SCIENCE@home

Real-world analysis and future trends of parkinson's disease burden and all-cause mortality in Shanghai Pudong: a population-based study of 3.17 million people

Zheng Luo,J. Xue,Yan Zhang,Yichen Chen,A. Fan,Ru Liu,Wenchang Jia,Xiaoling Wu,Qizhe Wang,Huihui Lv,Yong Bi,Xiaopan Li

Published 2025 in BMC Public Health

ABSTRACT

To assess all-cause Parkinson's disease (PD)-related and PD-specific mortality trends and years of life lost (YLL) in Shanghai Pudong (3.17 million population) from 2005–2021, and project future burdens through 2035. Using population-level mortality data including 4,218 PD-related deaths among 362,558 total deaths, we calculated crude mortality rates (CMR), age-standardized mortality rates (ASMRW), and YLL. Temporal trends were analyzed by the average annual percent change (AAPC) via Joinpoint regression, demographic impacts via decomposition methods, and future projections via ARIMA models. PD-related CMR and ASMRW were 8.74/100,000 and 2.76/100,000, respectively, with 31,904.41 YLL. PD-specific mortality rates (CMR: 3.76/100,000; ASMRW: 1.25/100,000) accounted for 14,532.50 YLL. Individuals aged ≥ 80 years exhibited highest mortality burden (CMR: 112.29/100,000). Cerebrovascular disease (18.94%) and coronary heart disease (13.54%) were leading comorbidities. Temporal analyses revealed significant annual increases in ASMRW (AAPC = 8.38%, P < 0.001) and YLL rates (AAPC = 7.03%, P < 0.001), driven predominantly by population aging (AAPC = 30.73%, P < 0.001). Projections indicate continued rises in ASMRW (AAPC = 1.49%) and YLL rates (AAPC = 3.49%) through 2035 (P < 0.001). PD imposes increasing mortality burden in Shanghai Pudong, with population aging as the primary driver. Multi-departmental interventions targeting early diagnosis, comorbidity management, and medical infrastructure are urgently needed. Clinical trial number: not applicable.

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-43 of 43 references · Page 1 of 1

CITED BY

  • No citing papers are available for this paper.

Showing 0-0 of 0 citing papers · Page 1 of 1